Stephen T. Sonis, DMD, DMSc Joins PlasmaTech Biopharmaceuticals' Scientific Advisory Board

DALLAS and NEW YORK, Nov. 4, 2014 /PRNewswire/ -- PlasmaTech Biopharmaceuticals, Inc. (OTCBB: ACCPD), a biopharmaceutical company advancing patient care in critical areas, announced that Stephen T. Sonis, DMD, DMSc has joined its Scientific Advisory Board (SAB).  A world-renowned expert in the clinical treatment and research of cancer-related mucosal toxicities, Dr. Sonis has collaborated with management in recent years on advancing the company's clinical efforts of its oral mucositis treatment, MuGard.

"We are grateful that Dr. Sonis has joined our SAB," stated Scott Schorer, CEO of PlasmaTech Biopharmaceuticals, Inc.  He continued, "Dr. Sonis is a formative force in the evolution of mucositis treatments, and his ability to provide us with critical insight has served as the cornerstone of our MuGard commercialization efforts.  His counsel will continue to be highly valuable to us as we advance additional products from our Polymer Hydrogel Technology (PHT) platform, such as  ProctiGard."   

"I'm very pleased to join the PlasmaTech Biopharmaceuticals SAB and to continue supporting the company's vision for MuGard as an effective palliative treatment for mucosal toxicities.   The lack of effective interventions for oral mucositis, a condition that negatively impacts the tolerability of cancer treatments, has been an ongoing frustration for healthcare providers and cancer patients.  MuGard's palliative effectiveness as demonstrated in a rigorous clinical trial has separated it from other currently available oral rinses and gels and set a new standard for agents in this class.  I also look forward to collaborating with PlasmaTech's scientific advisory board and management with other technologies and clinical indications."

About Stephen T. Sonis, DMD, DMSc 

Worldwide scientific and medical expert in oncology treatment-induced mucositis, Dr. Sonis currently serves as Clinical Professor of Oral Medicine at Harvard School of Dental Medicine, Senior Surgeon and Chief, Divisions of Oral Medicine at Brigham and Women's Hospital and the Dana-Farber Cancer Institute, and as Chief Scientific Officer of Biomodels, LLC.  He also serves as a consultant to a number of biotechnology and pharmaceutical companies, advising directly on the conduct of clinical trials of oral mucositis.  Throughout his career, Dr. Sonis has focused on the biology and clinical significance of cancer regimen-related mucosal toxicities.  In particular, Dr. Sonis was pivotal in identifying the crucial biological processes involved in the generation of severe oral mucositis. The results of his studies have provided treatment targets for biological and pharmaceutical development. Dr. Sonis and his collaborators have identified specific pathways that are critical in toxicity development and have used these to form the basis for models of gene-based risk prediction. Dr. Sonis has published and lectured extensively on the clinical, biological, and health economic aspects of cancer and complications associated with its treatment. He serves on a number of editorial boards, and is a founding member of the International Society of Oral Oncology and the International Academy of Oral Oncology. Dr. Sonis received his Doctor of Dental Medicine (DMD) from Tufts University, his Doctor of Medical Science (DMSc) from Harvard University and was a Knox Fellow at Oxford University.

About PlasmaTech Biopharmaceuticals, Inc.

Formerly Access Pharmaceuticals, Inc., PlasmaTech Biopharmaceuticals, Inc.™ is a biopharmaceutical company focused on advancing targeted treatments for significant unmet needs of critical patient care. Exploiting two proprietary platforms, Salt Diafiltration (SDF™) Process and Polymer Hydrogel Technology (PHT™), PlasmaTech Bio is active in the development and commercialization of plasma-derived therapeutics and cancer supportive care products. The company has a robust product pipeline that includes two commercial stage products, MuGard® and ProctiGard™, and multiple follow-on products in development.  For more information, visit www.plasmatechbio.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for MuGard and ProctiGard, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to PlasmaTech's need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in PlasmaTech's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission.

Company and Media Contact:
Christine Berni
Vice President, Corporate Development
PlasmaTech Biopharmaceuticals, Inc.
(212) 786-6208

SOURCE PlasmaTech Biopharmaceuticals, Inc.

Related Links

http://www.plasmatechbio.com